BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7647780)

  • 1. Mutations associated with familial melanoma impair p16INK4 function.
    Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
    Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
    Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
    Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
    Reymond A; Brent R
    Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
    Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P
    Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
    Noh SJ; Li Y; Xiong Y; Guan KL
    Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of germline CDK6 mutations in familial melanoma.
    Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
    Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
    Serrano M; Hannon GJ; Beach D
    Nature; 1993 Dec; 366(6456):704-7. PubMed ID: 8259215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.
    Parry D; Bates S; Mann DJ; Peters G
    EMBO J; 1995 Feb; 14(3):503-11. PubMed ID: 7859739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
    Wang YL; Uhara H; Yamazaki Y; Nikaido T; Saida T
    Br J Dermatol; 1996 Feb; 134(2):269-75. PubMed ID: 8746340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines.
    Timmermann S; Hinds PW; Münger K
    Cell Growth Differ; 1997 Apr; 8(4):361-70. PubMed ID: 9101082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
    Lukas J; Parry D; Aagaard L; Mann DJ; Bartkova J; Strauss M; Peters G; Bartek J
    Nature; 1995 Jun; 375(6531):503-6. PubMed ID: 7777060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
    Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
    Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
    Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.
    Hannon GJ; Beach D
    Nature; 1994 Sep; 371(6494):257-61. PubMed ID: 8078588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
    Zariwala M; Xiong Y
    Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.